LONG-TERM (UP TO 156 WEEKS) SAFETY PROFILE OF ORAL APREMILAST IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED ANALYSIS OF PALACE 1-3

Mease P. J.; Gladman D. D.; Gomez-Reino J. J.; Hall S.; Kavanaugh A.; Lespessailles E.; Schett G.; Shah K.; Teng L.; Wollenhaupt J.

首页> 外文期刊>Clinical and experimental rheumatology >LONG-TERM (UP TO 156 WEEKS) SAFETY PROFILE OF ORAL APREMILAST IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED ANALYSIS OF PALACE 1-3

【24h】

LONG-TERM (UP TO 156 WEEKS) SAFETY PROFILE OF ORAL APREMILAST IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED ANALYSIS OF PALACE 1-3

机译：周期性关节炎患者（最长156周）的口服止痛药的安全性概况：宫殿1-3的分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical and experimental rheumatology》 |2016年第4期|共1页
作者
Mease P. J.; Gladman D. D.; Gomez-Reino J. J.; Hall S.; Kavanaugh A.; Lespessailles E.; Schett G.; Shah K.; Teng L.; Wollenhaupt J.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类免疫性疾病;
关键词

相似文献

外文文献
中文文献

1. LONG-TERM (UP TO 156 WEEKS) SAFETY PROFILE OF ORAL APREMILAST IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED ANALYSIS OF PALACE 1-3 [J] . Mease P. J., Gladman D. D., Gomez-Reino J. J., Clinical and experimental rheumatology . 2016,第4期

机译：周期性关节炎患者（最长156周）的口服止痛药的安全性概况：宫殿1-3的分析
2. Low rates of major adverse cardiac events, malignancies, and serious infections in subjects with psoriasis and psoriatic arthritis treated with apremilast for = 156 weeks: pooled analysis from the ESTEEM and PALACE 1-3 phase 3 trials [J] . Kavanaugh A., Augustin M., Lespessailles E., Scandinavian journal of rheumatology . 2018,第Suppla129期

机译：患有牛皮癣和银屑病关节炎的主要不良心脏事件，恶性肿瘤和严重感染的低率＆ = 156周：从尊敬和宫内汇集分析1-3期3阶段试验
3. Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1) [J] . Gladman Dafna, Kavanaugh Arthur, Mease Philip, The Journal of rheumatology . 2015,第7期

机译：口服磷酸二酯酶4抑制剂Apremilast在银屑病关节炎患者中的长期（104周）疗效和安全性概况：III期，随机对照试验和开放标签扩展试验的结果（PALACE 1）
4. IMANI-1 TC3WP Single Drug HAART -Proof of Concept Study Pilot Study of the Safety and Efficacy of Kaletra (LPV/r) as Single Drug HAART in HIV+ ARV- Naive Patients - Interim Analysis of Subjects Completing Final 48 Week Data [C] . J.C. Gathe Jr., M. Washington, C. Mayberry International AIDS Conference . 2004

机译：Imani-1 TC3WP单药搭载概念研究试验试验研究Kaletra（LPV / R）作为艾滋病毒+ ARV天真患者单药HAART的安全性和有效性 - 临时分析受试者完成最终的48周数据
5. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis [O] . Arthur Kavanaugh, Dafna D. Gladman, Christopher J. Edwards, 2019

机译：银屑病关节炎患者长期使用前兆莫斯特的经验：PALACE 1-3汇总分析的5年结果
6. 166 Long-term (156-week) improvements in dactylitis and enthesitis with apremilast inpsoriatic arthritis subjects: analysis of a large, pooled PALACE 1-3 database [O] . Dafna D Gladman, Arthur Kavanaugh, Juan J Gomez-Reino, 2018

机译：166年长期（156周）改善直仙炎和诱滞性关节炎主题：分析大型，合并宫殿1-3数据库

LONG-TERM (UP TO 156 WEEKS) SAFETY PROFILE OF ORAL APREMILAST IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED ANALYSIS OF PALACE 1-3

著录项

相似文献

相关主题

期刊订阅